Siltuximab + Epcoritamab
Phase 1Recruiting 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Hodgkin Lymphoma
Conditions
Non-Hodgkin Lymphoma, Cytokine Release Syndrome
Trial Timeline
Jan 14, 2025 โ Sep 1, 2028
NCT ID
NCT06447376About Siltuximab + Epcoritamab
Siltuximab + Epcoritamab is a phase 1 stage product being developed by AbbVie for Non-Hodgkin Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06447376. Target conditions include Non-Hodgkin Lymphoma, Cytokine Release Syndrome.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06447376 | Phase 1 | Recruiting |
Competing Products
20 competing products in Non-Hodgkin Lymphoma